Ministry of Health and Family Welfare has reported the national recovery rate at 96.78 per cent.
Amid huge speculations and controversy around the clinical trial of India’s first indigenous nCoV vaccine i.e. Covaxin, renowned medical journal Lancet has reported it to lead tolerable safety outcomes and enhanced immune responses.
It has come out as big news as the Bharat Biotech’s vaccine was granted Emergency Use Authorisation (EUA) despite the fact that its Phase III efficacy trials are underway.
The India Council of Medical Research has crossed the 19 crores (190 million) RT-PCR and antigen tests to detect SARS-CoV-2 -- the virus behind Covid-19 pandemic, an ICMR official told media.
As per some official sources, as India approaches phase II of the vaccination drive, Prime Minister Modi and other politicians over 50 years of age are eligible to receive the shots. (UNI)